...
首页> 外文期刊>International Journal of Pharmaceutics >Increasing the dissolution rate and oral bioavailability of the poorly water-soluble drug valsartan using novel hierarchical porous carbon monoliths
【24h】

Increasing the dissolution rate and oral bioavailability of the poorly water-soluble drug valsartan using novel hierarchical porous carbon monoliths

机译:使用新型的分级多孔碳整料提高水溶性差的缬沙坦的溶出度和口服生物利用度

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In the present study, a novel hierarchical porous carbon monolith (HPCM) with three-dimensionally (3D) ordered macropores (<400 nm) and uniform accessible mesopores (<5.2 nm) was synthesized via a facile dual-templating technique using colloidal silica nanospheres and Poloxamer 407 as templates. The feasibility of the prepared HPCM for oral drug delivery was studied. Valsartan (VAL) was chosen as a poorly water-soluble model drug and loaded into the HPCM matrix using the solvent evaporation method. Scanning electron microscopy (SEM) and specific surface area analysis were employed to characterize the drug-loaded HPCM-based formulation, confirming the successful inclusion of VAL into the nanopores of HPCM. Powder X-ray diffraction (PXRD) and differential scanning calorimetry (DSC) demonstrated that the incorporated drug in the HPCM matrix was in an amorphous state and the VAL formulation exhibited good physical stability for up to 6 months. In vitro tests showed that the dissolution rate of HPCM-based formulation was increased significantly compared with that of crystalline VAL or VAL-loaded 3D ordered macroporous carbon monoliths (OMCMs). Furthermore, a pharmacokinetic study in rats demonstrated about 2.4-fold increase in oral bioavailability of VAL in the case of HPCM-based formulation compared with the commercially available VAL preparation (Valzaar ? These results therefore suggest that HPCM is a promising carrier able to improve the dissolution rate and oral bioavailability of the poorly water-soluble drug VAL.
机译:在本研究中,通过使用胶体二氧化硅纳米球的简便双模板技术合成了具有三维(3D)有序大孔(<400 nm)和均匀可及的中孔(<5.2 nm)的新型分层多孔碳整料(HPCM)。和泊洛沙姆407作为模板。研究了制备的HPCM用于口服药物递送的可行性。选择缬沙坦(VAL)作为水溶性差的模型药物,并使用溶剂蒸发法将其加载到HPCM基质中。扫描电子显微镜(SEM)和比表面积分析被用来表征载药的基于HPCM的制剂,证实VAL成功地包含在HPCM的纳米孔中。粉末X射线衍射(PXRD)和差示扫描量热法(DSC)证明,在HPCM基质中掺入的药物处于非晶态,并且VAL制剂显示长达6个月的良好物理稳定性。体外测试表明,与结晶VAL或VAL加载的3D有序大孔碳整料(OMCM)相比,基于HPCM的制剂的溶出速率显着提高。此外,在大鼠中进行的药代动力学研究表明,与市售的VAL制剂相比,基于HPCM的制剂口服VAL的生物利用度提高了约2.4倍(Valzaar®)。水溶性差的药物VAL的溶出度和口服生物利用度

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号